Global Head, Research & Development
Martin Fitchet, M.D. is Global Head, Research & Development for Johnson & Johnson Medical Devices. In this role, he is responsible for all aspects of Research & Development across the company’s 3 Medical Devices franchises – DePuy Synthes, Ethicon and Cardiovascular & Specialty Solutions. Martin is a member of the Johnson & Johnson Medical Devices Group Operating Committee and the Johnson & Johnson Research & Development Management Committee.
Prior to his current role, Martin served as Global Head of Research & Development for the DePuy Synthes Companies of Johnson & Johnson. In this role, he oversaw new product development, portfolio prioritization and resource allocation for global orthopaedics.
First joining Johnson & Johnson in 2000, Martin has held several positions of increasing responsibility, including Chief Operating Officer, Research & Development for the Janssen Pharmaceutical Companies of Johnson & Johnson, where he oversaw operational excellence and execution of clinical development programs with the goal of driving maximum effectiveness and efficiency in bringing new drugs to market. Martin also held the position of Global Therapeutic Area Head for Cardiovascular & Metabolism Research & Development and Global Head of Internal Medicine for the CNS/Internal Medicine franchise, with responsibility for the development of metabolic, gastrointestinal and antibiotic compounds. He also held scientific leadership positions in Medical Affairs and Research & Development for Sanofi Aventis and Novartis.
Having earned his medical degree at the University of Nottingham Medical School in Nottingham, UK, Martin became a Fellow of the Royal College of Surgeons of England in 1995, later becoming an Associate of the Faculty of Pharmaceutical Medicine in London, UK.
1 blog from the author
Posted on 20.12.2016
Reach More Patients. Restore More Lives.
A 2015 report from The Lancet Global Surgery Commission found that nearly one-third of the global burden of disease can be treated surgically and that 5 billion people lack access to safe and affordable surgical care. At Johnson & Johnson, we are looking to improve the standard of care and treatment, accelerating our pace of […]